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Abstract
Diabetic retinopathy causes the plurality of blindness among the working class of America. This
review focuses on the biochemistry and pathophysiology of the pancreatic cells during the
development of diabetes as well as the effects that diabetes has on the Müller cells and pericytes
of the retina at the cellular and molecular levels. In addition, the current research on some of the
treatment options for diabetic retinopathy will be presented. This review is valuable to the
scientific community because it presents a side-by-side summary of the pathogenesis of diabetes
and diabetic retinopathy based on the current body of research.
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The Pathogenesis of Diabetes and Its Negative Impact on the Retina: Diabetic Retinopathy
Introduction
Diabetes is on the rise in the United States, and the current trends suggest it is likely to
continue rising in the coming years. The prevalence of diabetes in the United States increased
from 9.5% to 12.0% between 2002 and 2016 (Center for Disease Control and Prevention, 2020).
Furthermore, in 2018, an estimated 13.0% of American adults had diabetes, whether diagnosed
or undiagnosed. Among other symptoms, diabetes can result in increased thirst, fatigue, muscle
breakdown, and obesity. Because diabetes affects such a broad range of people in a variety of
ways, researchers are constantly seeking to better understand the disorder and come up with new
and more effective treatments. To create effective treatments, researchers must understand the
pathogenic mechanisms of the two types of diabetes.
Diabetes results from damage to the cells of the pancreas and is divided into two main
categories: type I diabetes and type II diabetes. In brief, type II diabetes is commonly associated
with lifestyle choices such as a high-glucose diet which allows for consistently high
concentrations of glucose in the blood. Type I diabetes, on the other hand, is the result of an
autoimmune disorder in which the cells of the immune system attack and kill the cells of the
pancreas. As will be described later, prolonged hyperglycemia causes damage and death to the
cells of the pancreas. Without the proper functioning of the pancreatic cells, the body
experiences an inability to produce the hormones necessary to regulate blood glucose levels. One
of the most common symptoms of diabetes is diabetic retinopathy. Not only is diabetic
retinopathy the most common complication of diabetes, but it is also the leading cause of
blindness among working-age Americans (Lee et al., 2015; Wang & Lo, 2018). Similar to its
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effects on the cells of the pancreas, hyperglycemia damages and kills the vascular and neural
cells of the retina. This results in retinal hypoxia, ocular malnutrition, and further destruction of
the retina. This review focuses on the causes and development of diabetes and pathology of
diabetic retinopathy. In addition, treatment options and current research surrounding the diseased
state will be discussed.
The Normal Functioning of the Pancreas and Blood Glucose Regulation
Blood glucose levels are tightly regulated to maintain homeostasis in the organism. Low
levels of glucose in the blood, hypoglycemia, decreases the body’s readily available nutrients
and can result in shakiness, nausea, and decreased cognitive ability and awareness. Conversely,
high levels of glucose in the blood, hyperglycemia, cause an increase in the body’s metabolism
which results in oxidative stress and subsequent damage to various cell types. The pancreas is the
major regulatory organ of blood glucose levels. The endocrinal structures of the pancreas are
referred to as the Islets of Langerhans and includes various cell types which play a role in
maintaining blood glucose homeostasis.
The Cells of the Pancreas
The Islets of Langerhans are important endocrine structures involved in regulating
various metabolic functions (Xavier, 2018). While the islets are composed of other cells such as
pancreatic-polypeptide-hormone-releasing γ-cells, ghrelin-releasing ε-cells, and somatostatinreleasing δ-cells, the two major types of islet cells focused on in this review are the α-cells and βcells. α-cells release glucagon to promote glycogen breakdown into glucose and increase blood
glucose levels, while β-cells release insulin to promote glucose storage into glycogen and
decrease blood glucose levels. By volume, α-cells and β-cells make up the majority of the
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pancreatic islets. While γ-cells, ε-cells, and δ-cells combined account for roughly 10% of the
Islets of Langerhans, the α-cells and β-cells represent 30% and 60% of the islets, respectively
(Xavier, 2018). In addition to secreting hormones to adjust blood glucose levels, α-cells and βcells are able to sense the concentration of glucose in the blood. The pancreas is highly
vascularized so it can sense and respond to blood glucose levels in an accurate and timely
fashion (Quesada et al., 2008). Blood passes through the β-cells which are closest to
vascularization first, followed by the α-cells, and finally to the rest of the cells in the Islets of
Langerhans. In order to accurately sense glucose concentrations in the blood, α-cells and β-cells
must have a reliable means of transporting glucose from the blood into the cell.
Via facilitated diffusion, glucose transporters (GLUTs) within the plasma membranes of
both α-cells and β-cells provide the ability to monitor the glucose concentration of the blood as it
passes through the pancreas (Berger & Zdzieblo, 2020). In the β-cells, GLUT2 is the transporter
primarily responsible for moving glucose across the plasma membrane. In contrast, GLUT1
appears to be the primary transporter of glucose across the membranes of α-cells. Facilitated
diffusion of glucose across the membranes of α-cells and β-cells allows for an accurate
measurement of blood glucose levels because facilitated diffusion relies solely on the
concentration gradient. Therefore, the higher the concentration of glucose in the blood, the more
glucose is transported through GLUT2 and GLUT1, and the higher the glucose concentration is
inside the α-cells and β-cells, respectively. Although the initial means of glucose transport is
very similar for both the α-cells and β-cells, each responds to glucose in a very different way.

DIABETES AND ITS IMPACT ON THE RETINA

7

Normal Functioning of Pancreatic β-Cells
In β-cells, the mechanism by which glucose signals for the release of insulin is dependent
on fluctuations in the voltage potential across the membrane. In low blood glucose conditions
(< 3 mM), antiport ion exchange pumps drive calcium (Ca2+) ions out of the cell by using the
concentration gradient of sodium (Na+) ions (Gylfe, 2016; Klec et al., 2019). These Na+-Ca2+ ion
exchange pumps bring Na+ ions into the cell passively because the extracellular concentration of
Na+ ions is much greater than the intracellular concentration. However, in order for Na+ ions to
be transported via this exchange pump, the pump must bind Ca2+ ions from the inside of the cell
and transport it outwardly. Thus, Ca2+ ions are driven out of the cell against their concentration
gradient. At the same time, ATP-dependent potassium (K+) ion channels are open and allow for
facilitated diffusion of K+ ions from inside the cell to the outside of the cell along their
concentration gradient. This outward flow of positively charged K+ ions allows the β-cells to
reach and maintain a hyperpolarized resting membrane potential of -70 mV while the blood has
relatively low levels of glucose (Rorsman & Ashcroft, 2018).
In hyperglycemic conditions (>5-7 mM), the process by which β-cells respond by
secreting insulin starts with an increased transportation of glucose across the plasma membrane
via GLUT2 transporters (Gylfe, 2016). The glucose is transported into the β-cells by facilitated
diffusion along its concentration gradient. The higher the concentration of glucose in the
bloodstream, the greater the concentration gradient and the more glucose is transported into the
cell. Once the glucose has crossed the plasma membrane, it begins the process of glycolysis.
According to Le Chatelier’s principle, a chemical reaction at equilibrium will shift forwards or
backwards in response to an excess of reactants or products, respectively (Rietman et al., 2013).
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In the case of a sudden increase in intracellular glucose, glycolysis is no longer at equilibrium.
Since glucose is a reactant in this reaction, the influx of glucose causes the reaction to shift
strongly towards the product: ATP.
An increased ATP/ADP ratio affects ion channels embedded in the plasma membrane
and ultimately releases insulin into the bloodstream. First, the greater ATP/ADP ratio inside the
β-cells results in the closure of ATP-dependent K+ ion channels (Jacobson et al., 2009). Without
the constant flow of K+ ions leaving the cell, the membrane potential becomes less negative
because positively charged K+ ions stay in the cell. Depolarization of the cell due to ATPdependent K+ ion channel closure causes L-type voltage-gated Ca2+ ion channels to open
resulting in a sudden influx of Ca2+ ions along their concentration gradient (Klec et al., 2019).
Ca2+ ions act as intracellular signals to initiate the transport of insulin-containing vesicles
towards the plasma membrane. Research has demonstrated that a limited number of soluble Nethylmaleimide-sensitive factor attachment protein receptor proteins (SNAREs) are responsible
for the fusion of these vesicles with the plasma membrane. Namely, synaptobrevin-2, syntaxin-1,
and SNAP-25 facilitate the exocytosis of insulin from β-cells (Rӧder et al., 2016).
Synaptobrevin-2, lodged in the plasma membrane of the vesicle, binds to syntaxin-1 and SNAP25 on the inner-surface of the cell’s plasma membrane. These SNARE proteins remove the
cytoplasm between the vesicle and the cell wall causing the fusion of phospholipid bilayers and
the secretion of insulin into the bloodstream (Fasshauer et al. 1997).
In contrast, at a low concentration of glucose in the blood, β-cells have minimal amounts
of glucose transported across the GLUT2 due to a smaller concentration gradient. Thus,
glycolysis proceeds at a slower rate and the intracellular ATP/ADP ratio is relatively small. A

DIABETES AND ITS IMPACT ON THE RETINA

9

small ATP/ADP ratio allowed ATP-dependent K+ ion channels to remain open and β-cells to
remain polarized at a membrane potential of -70 mV (Rӧder et al., 2016; Rorsman & Ashcroft,
2018). At this membrane potential, there are no action potentials generated, no influx of Ca2+
ions, and therefore, no secretion of insulin.
Normal Functioning of Pancreatic α-Cells
α-cells, just as β-cells, respond to glucose via the opening and closing of ion channels and
the rise and fall of action potentials. However, α-cells respond to glucose concentrations in a
very different way compared to β-cells. In hypoglycemic conditions, GLUT1 transports less
glucose into α-cells because there is a relatively low concentration gradient (Berger & Zdzieblo,
2020). Again, according to Le Chatelier’s principle, low levels of glucose cause the glycolysis
equilibrium to favor gluconeogenesis (Rietman et al., 2013). Therefore, less ATP is made and the
ATP/ADP ratio is rather low. In such conditions, ATP-dependent K+ ion channels are allowed to
function with moderate activity facilitating the exit of K+ ions along their concentration gradient
(Quesada et al., 2008). The consistent flow of positively charged K+ ions to the outside of the
cell brings α-cells to an ideal membrane potential of about -60 mV. At this potential, T-type
voltage-gated Ca2+ ion channels open and cause an influx of Ca2+ ions along their concentration
gradient. This influx begins the depolarization of α-cells and initiates an action potential.
Once the Ca2+ ion influx from the T-type voltage-gated Ca2+ ion channels begins
depolarization, voltage-gated Na+ ion channels open and cause an influx of Na+ ions to further
depolarize the cell until it reaches a membrane potential between -40 and -30 mV (Quesada et
al., 2008). At this membrane potential, voltage-gated L-type Ca2+ ion channels and voltage-gated
N-type Ca2+ ion channels open. The L-type Ca2+ ion channels are the primary conduit of Ca2+
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ions and are therefore largely responsible for completing the action potential. The N-type Ca2+
ion channels on the other hand are needed to transport the Ca2+ ions that trigger the release of
glucagon. Although the mechanism by which only the Ca2+ ions from N-type Ca2+ ion channels
trigger release of glucagon is not fully understood, research demonstrates that only the N-type
Ca2+ ion channels are involved in triggering exocytosis of glucagon (Gromada et al., 2004).
When the L-type Ca2+ ion channels have completed α-cell depolarization, voltage-gated
A-type K+ ion channels open and allow for the efflux of K+ ions from the cell once again
(Quesada et al., 2008). Since intracellular K+ ion concentrations are relatively high, the K+ ions
rush outwards along their concentration gradient. This rapid efflux of positively charged K+ ions
repolarizes the cell until, with the help of open ATP-dependent K+ ion channels, it once again
reaches a membrane potential of -60 mV. At this stage, the T-type Ca2+ ion channels are poised
to reopen and begin a new action potential. Thus, at low levels of glucose, action potentials are
generated repeatedly to allow for the consistent release of glucagon until blood glucose
concentration increase.
When blood glucose concentrations are elevated, GLUT1 transports greater amounts of
glucose into the cell because of the increased concentration gradient. Glucose enters the process
of glycolysis to generate more ATP and subsequently increase the ATP/ADP ratio. Greater
amounts of ATP in α-cells result in closure of ATP-dependent K+ ion channels so the cells are
depolarized. Without the moderate activity of ATP-dependent K+ ion channels allowing for the
efflux of K+ ions, the α-cells settle at a resting membrane potential which is less negative than
-60 mV (Quesada et al., 2008). At this membrane potential, T-type Ca2+ ion channels are
rendered inactive and the cell is unable to produce an action potential. Without the opening of T-
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type Ca2+ ion channels, α-cells are not depolarized, N-type Ca2+ ion channels remain closed, and
glucagon exocytosis is not initiated. Therefore, high blood glucose concentrations inhibit the
release of glucagon from α-cells.
The Pathogenesis of the Diabetic Pancreas
Pathogenesis in Type II Diabetes
Under certain circumstances, the glucose dependent regulation of blood glucose levels is
disrupted and homeostasis is disturbed. Diabetes is characterized by hyperglycemia; however,
not only does diabetes cause hyperglycemia, but in the case of type II diabetes, hyperglycemia
can cause diabetes (Cerf, 2013). As described above, hyperglycemia causes an increased
intracellular concentration of glucose in α-cells and β-cells. In controlled amounts, this is a good
and normal process. However, chronic hyperglycemia causes overstimulation of mitochondria,
dysfunction of insulin and glucagon secretion, and cellular death.
Increased intracellular glucose concentrations stimulate an increased rate of glycolysis
which reduces intracellular glucose concentration while raising levels of pyruvate. Pyruvate is
transported to the mitochondria and converted to Acetyl-CoA to be used in the Kreb’s cycle. The
Kreb’s cycle uses Acetyl-CoA to generate high energy electrons in the form of NADH and
FADH. These high energy electrons are used in the electron transport chain to generate the major
source of cellular energy, ATP. Naturally, the electron transport chain generates reactive oxygen
species (ROS). In a state of chronic hyperglycemia, however, overstimulation of the electron
transport chain creates elevated levels of ROS which damage and kill α-cells and β-cells.
Furthermore, many researchers conclude the islets of the pancreas are especially susceptible to
oxidative stress because they produce less antioxidants compared to other organs (Cerf, 2013;

DIABETES AND ITS IMPACT ON THE RETINA

12

Kim et al., 2017). To counter the dangerous effects of oxidative stress, α-cells and β-cells
respond in different ways.
ROS are multipurpose intracellular signals. ROS can signal for cell proliferation as well
as cellular death (Kim et al., 2017). These opposite effects to the same signal depend largely on
the cell’s ability to upregulate phosphoinositide 3-kinase (PI3K) and protein kinase B (Akt). If
the cell is able to upregulate PI3K and Akt, such as in α-cells, then increased cell proliferation is
signaled. In contrast, β-cells are unable to activate PI3K and Akt signaling. Instead, β-cells
activate Forkhead box gene, group O (FoxO) in an attempt to resist oxidative stress. FoxO is a
transcription factor that causes increased expression of antioxidant genes, especially manganese
superoxide dismutase (MnSOD), to counter the effects of oxidative stress. To summarize, α-cells
respond to ROS by secreting proliferation factors and replacing the cells induced to apoptosis by
ROS. β-cells, on the other hand, increase transcription of antioxidants in an effort to counter the
oxidative stress imposed by ROS.
In prolonged hyperglycemic states, the α-cells’ method of survival outcompetes that of
the β-cells. Although -cells produce more antioxidant, they are unable to produce enough to
counter rapid production of ROS via the electron transport chain (Kim et al., 2017). Furthermore,
research demonstrates that hyperglycemia inhibits β-cell proliferation, so they are unable to
proliferate at a rate fast enough to counter the increased rate of apoptosis due to ROS damage.
Thus, β-cells die at a much faster rate than do α-cells, and consequently, α-cells make up a
greater percentage of the pancreatic islets. β-cell death is responsible for many of the
downstream implications involved with diabetes. The pathogenesis of type I diabetes involves
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the death of β-cells, too. However, the process by which β-cells die in type I diabetes is much
different than in type II diabetes.
Pathogenesis in Type I Diabetes
Clearly, hyperglycemia has detrimental effects on the pancreas. Hyperglycemia is a
major concern for people with type I diabetes as well as in individuals with type II diabetes;
however, the pathogenesis of type I diabetes is quite different from that of type II diabetes. While
in type II diabetes, β-cell death is caused by oxidative stress in response to hyperglycemia, type I
diabetes is an autoimmune disorder in which β-cells are killed by the cells of the immune system.
Any time the pathogenesis of an autoimmune disease is considered, it is necessary to think about
the topic of immune tolerance. Tolerance, the ability of the immune system to eliminate or
suppress auto-reactive immune cells, can be broken down into two main categories: central
tolerance and peripheral tolerance. Defects in either of these systems can lead to the development
of an autoimmune disease.
In some cases, β-cell autoreactivity is the result of T cells evading central tolerance. For
some patients with type 1 diabetes, the Autoimmune Regulator (AIRE) gene is not present or is
not functioning at normal levels due to genetic inheritance (Cheng & Anderson, 2013). Many
pancreatic autoantigens such as proinsulin are dependent on AIRE for their expression by
medullary thymic epithelial cells (mTECs) in the thymus. Therefore, in people with less than
adequate or with no expression of the Aire protein, mTECs are unable to negatively select
autoreactive T cells. These autoreactive T cells are allowed to leave the thymus and enter
circulation where they make their way to susceptible β-cells and kill them. In addition to central
tolerance, peripheral tolerance is typically impaired in individuals who develop type I diabetes
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(Kwong et al., 2021). Multiple studies have demonstrated that patients with type I diabetes
exhibit decreased levels of regulatory T (Treg) cells which inhibit their ability to suppress the
immune response against autoantigens (Atkinson et al., 2014; Graham et al, 2012). Without the
proper response of Treg cells to suppress immune function, autoreactive T cells are allowed to
kill β-cells without regulation. This also helps to explain why β-cell death occurs much more
rapidly in type I diabetes compared to type II diabetes (Sarikonda et al., 2014). Whether by
failure of central tolerance or peripheral tolerance, the immune cells of patients with type I
diabetes attack and kill β-cells.
In some instances, type I diabetes is brought on by environmental factors instead of
genetic factors. One common theory is that environmental factors could cause initiation of mild,
controlled inflammation which could progress to uncontrolled, chronic inflammation and
autoimmunity (Bettini & Vignali, 2011). For example, viral infection with a pathogen that affects
the pancreas could cause T cells to rightfully attack β-cells in order to stop the infection. As the
β-cells die, the result is mild, controlled inflammation of the pancreas. However, in some cases,
allowing T cells to attack the β-cells of the pancreas could create memory T cells that recognize
components of β-cells. After the initial infection, one of these memory cells may recognize and
attack the β-cells which would create a stronger immune response than before. Thus, pathogen
infection can lead to type I diabetes because of normal immune function.
The Consequences of β-cell Death
The death of β-cells and concurrent survival of α-cells creates problems for blood glucose
regulation. First, with decreases in the number of β-cells, insulin secretion is impaired and
glucose uptake from the blood is decreased (Cerf, 2013). This leaves more glucose in the blood
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and contributes to the hyperglycemic state. In addition, many researchers call diabetes a “bihormonal” disease, because abnormal levels of both insulin and glucagon secretions contribute to
hyperglycemia (Kim et al., 2017). In fact, some research demonstrates that impaired insulin
secretion may cause dysfunction of glucagon-secreting α-cells. The secretion of glucagon by αcells is dependent not only on blood glucose levels, but also on insulin secretion by β-cells
(Cryer, 2012). In the properly functioning pancreas, the rise and fall of insulin secretion is
inversely correlated to the secretion of glucagon. Thus, elevation in insulin secretion inhibits
glucagon secretion, and cessation of insulin secretion stimulates glucagon secretion. In diabetes,
it is observed that the decreased insulin secretion due to apoptosis of β-cells stimulates an
increase in glucagon secretion from α-cells despite high levels of glucose in the blood. In turn,
glucagon release stimulates the liver to break down glycogen into glucose to be released into the
bloodstream furthering the problem of hyperglycemia. At this point in the progression of both
type I and type II diabetes, the pancreas loses regulatory ability over blood glucose
concentrations and the body experiences a chronic state of hyperglycemia.
The Normal Functioning of Retinal Cells
As briefly described above, diabetes has a wide range of negative implications for the
body. Of these negative implications, diabetic retinopathy is the most common microvascular
complication in patients with diabetes (Wang & Lo, 2018). Chronic hyperglycemia has
detrimental effects on the cells of the retina. Specifically, diabetes causes dysfunction and death
of retinal Müller cells and pericytes.
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Müller Cell Function
Müller cells perform various functions in the retina including regulating immune
responses, regulating inflammation, structurally stabilizing the retina, and promoting the survival
of photoreceptors and neurons by secreting trophic substances and removing metabolic waste
(Bringmann & Wiedemann, 2012). In addition to these important functions, Müller cells are
responsible for uptake of glutamate and production of glutathione (Bringmann & Wiedemann,
2012; Li & Puro, 2002; Muller et al., 1998). Glutamate is the major excitatory neurotransmitter
of the retina and can excite more than 90% of the synapses in the retina (Li & Puro, 2002; Muller
et al., 1998). Not only are Müller cells needed for the proper function of synapse excitation, but
retinal neurons are also dependent on Müller cells for their survival. Without the function of
Müller cells to remove glutamate from the retina, prolonged excitation of glutamate receptors
kills retinal neurons. In fact, glutamate toxicity is one of the primary mechanisms by which
neuronal cells die in many retinal disorders (Bringmann & Wiedemann, 2012).
Müller cells are responsible for the uptake of glutamate to ensure proper neuronal
signaling and prevent cell death from overexcitation. In addition, Müller cells use glutamate to
produce glutathione which is a vital antioxidant. The process of synthesizing glutathione requires
Müller cells to transport glutamate, cysteine, and glycine intracellularly from their surroundings
(Bringmann & Wiedemann, 2012). Glutathione is a critical mediator in the hostile environment
of the retina because the retina produces more oxidative stress than any other place in the body
(Kowluru & Chan, 2007). One potential reason why the retina is more susceptible to oxidative
stress is that it uses a large amount of energy and therefore has a higher oxygen uptake and
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glucose oxidation than any other tissue. Glutathione is the retina’s main defense against these
extreme amounts of oxidative stress and Müller cells are primarily responsible for its production.
Pericyte Function
The primary responsibility of pericytes is to surround and stabilize the microvasculature
of the retina. Pericytes have finger-like extensions that intertwine with each other to form a
stable network of cells surrounding the blood vessels. In the development of the retina, pericytes
perform important functions such as regulation of endothelial cell growth (Ejaz et al., 2007).
When the eye is developing, pericytes release pro-angiogenic cytokines which signal endothelial
cells to proliferate so the retina is properly vascularized to receive the nutrients necessary for the
high-energy functions it must perform. Once pericytes have matured, they become more
angiostatic in nature to prevent further proliferation of endothelial cells and prevent the
development of new blood vessels (Kremer et al., 2020). Clearly, pericyte function is vital to a
healthy retina.
The Pathogenesis of the Diabetic Retina
Diabetic retinopathy is a disorder of the retina that primarily affects the microvasculature
(Wang & Lo, 2018). However, if left unchecked, the problems involved in a diabetic retina can
lead to neuronal cell death and eventually blindness. Diabetic retinopathy can be classified into
two categories. Non-proliferative diabetic retinopathy is the early stage of the disease and is
commonly characterized by increases in vascular permeability and capillary occlusions. The
latter of the two can lead to microaneurysms and hemorrhages. Despite the extensive turmoil of
the inner eye, patients with non-proliferative diabetic retinopathy are typically asymptomatic at
this point in the disease. Upon progression of the diseased state, the patient enters the second
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stage of diabetic retinopathy which is called proliferative diabetic retinopathy. This stage of the
disease is more advanced and is commonly characterized by angiogenesis. Angiogenesis is the
formation of new blood vessels and is common in the pathology of diabetic retinopathy as well
as other diseases such as cancer and psoriasis (Paulas & Sodhi, 2017). In proliferative diabetic
retinopathy, angiogenesis is dangerous for multiple reasons mainly pertaining to the structural
integrity of the new blood vessels as well as their lack of directional growth. Blindness is the
major concern and ultimate result of damage to the retina; therefore, it is important to understand
how diabetic retinopathy damages the specific cells of the eye.
Hyperglycemia and Müller Cells
As is the threat to most cells in hyperglycemic conditions, the cells of the retina are
endangered by the increased presence of ROS. In a similar way to α-cells and β-cells, the
increased production of ROS in the retina is because of overstimulation of the mitochondria.
Therefore, glucose is metabolized at a greater rate due to the excessive amounts of intracellular
glucose. The primary contributor to ROS in the retina is the photoreceptor cells which have more
mitochondria compared to any other cell type in the retina (Kang & Yang, 2020). One of the
main cell types affected by increased ROS are Müller cells.
Hyperglycemia can cause Müller cell dysfunction by impairing transporter function (see
Figure 1). As described above, Müller cells are responsible for the uptake of glutamate and the
production of the major antioxidant glutathione. An aspect of Müller cells that makes them well
suited for this function is that they have redox-sensing glutamate transporters (Li & Puro, 2002).
Under normal conditions, this transporter regulates the amount of glutamate uptake via thioldisulfide redox interconversions. In hyperglycemic conditions, however, glutamate transport is
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disrupted which has major implications for the retina and specifically the Müller cells. When
studying the glutamate transporter of Müller cells, the research team of Muller et al. (1998)
observed a dose-dependent decrease in glutamate uptake by Müller cell transporters in response
to hydrogen peroxide. In addition, research done by Li and Puro (2002) demonstrated a 67%
decrease in transporter activity in the Müller cells of mice thirteen weeks after the development
of diabetes. Furthermore, in this same study, Li and Puro found that treating the Müller cells with
disulfide-reducing agents fully and rapidly restored the glutamate transporter activity.
Figure 1
Hyperglycemia Causes Müller Cell Dysfunction

The summation of these studies indicates two things. First, efficiency of glutamate
transport in Müller cells is directly affected by the oxidative conditions of the retina. Second,
excessive amounts of oxidative stress lead to transporter dysfunction via oxidation of thioldisulfides. Consequently, transporter dysfunction further damages the retina by decreasing
glutamate uptake. The increased concentration of glutamate in the retinal environment causes
neural cell apoptosis via excitotoxicity (Bringmann & Wiedemann, 2012). As mentioned before,
glutamate is the major excitatory neurotransmitter in the retina and excessive stimulation due to a
lack of glutamate uptake is one of the most common causes of neuronal cell death in retinal
diseases. Glutamate transporter dysfunction not only causes damage to the retina due to a
decrease in glutamate uptake by the Müller cells, but also due to a decrease in glutathione
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production. Since glutathione is the major antioxidant of the retina, a decrease in its production
only exaggerates the problem of oxidative stress. This puts the retina into a positive feedback
system in which elevated ROS decrease glutathione production causing further elevation of
ROS.
Oxidative stress affects Müller cells by shutting down their glutamate transporters, but it
also induces Müller cell apoptosis (see Figure 2). In addition to mitochondrial overstimulation,
hyperglycemic conditions cause mitochondrial dysfunction (Tien et al., 2017). Inside the cell,
mitochondria are constantly colliding and combining to form bigger mitochondria as well as
splitting to form smaller mitochondria. This process is called fusion and fission, respectively.
Some research suggests that high glucose levels disrupt mitochondrial fusion and fission.
According to the research done by Tien et al. (2017), when exposed to high glucose levels,
Müller cells’ mitochondria demonstrated increased mitochondrial fragmentation as well as
decreased oxygen consumption.
Figure 2
Hyperglycemia causes Müller cell apoptosis

Upon dysfunction of the mitochondria, cells are programmed to induce apoptosis. This is
done by the release of pro-apoptotic markers. In the same research done by Tien et al. (2017),
mitochondrial dysfunction was observed concurrently with a significant increase in cytochrome c
release. Cytochrome c is released from the mitochondria to signal the cell to induce apoptosis.
Moreover, cytochrome c is not the only pro-apoptotic marker observed in Müller cells when
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exposed to high glucose concentrations. Caspase-3, Fas, and Bax have all been found in elevated
amounts in the diabetic retina (Abu El-Asrar et al., 2004). The combination of these apoptotic
markers makes it clear that high glucose is inducing Müller cell death. Apoptosis of Müller cells,
like glutamate transporter dysfunction, poses serious risk to the other cells of the retina. Due to
Müller cell apoptosis, the retina has fewer cells able to remove glutamate, synthesize glutathione,
release trophic factors, and remove metabolic waste. Importantly, with fewer Müller cells, there
is less support for the pericytes surrounding the retinal microvasculature.
Hyperglycemia and Retinal Pericytes
Oxidative stress is the driving force of diabetic diseases. Oxidative stress causes
apoptosis in α-cells, β-cells, and Müller cells, and as could be predicted, oxidative stress causes
apoptosis in retinal pericytes (see Figure 3). One way that oxidative stress signals for apoptosis
in pericytes is by causing the activation of nuclear factor κB (NF-κB) which is a transcription
factor for important pro-apoptotic and pro-inflammatory genes (Romeo et al., 2002). The
mechanism by which ROS lead to activation of NF-κB includes activity from high mobility
group box 1 (HMGB1) (Nebbioso et al., 2020). HMGB1 is equipped with redox sensing ability
via the presence of disulfide bridges and its function is dependent on the redox state of its
immediate environment. As oxidative stress increases in response to hyperglycemia, HMGB1
becomes oxidized from its reduced form into the disulfide form. In its disulfide form, HMGB1 is
able to activate NF-κB. When inactivated, NF-κB is bound by inhibitory κB proteins (IκB)
(Romeo et al., 2002). In its disulfide state, HMGB1 is able to direct phosphorylation and
subsequent degradation of IκB. Without this inhibitory molecule, NF-κB is free to translocate to
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the nucleus of the cell where it increases expression of pro-apoptotic factors such as Bax and
pro-inflammatory factors such as TNF-α (Suryavanshi & Kulkarni, 2017).
Figure 3
Hyperglycemia Causes Pericyte Apoptosis

Pericyte apoptosis is extremely dangerous to the diabetic retina. Most researchers agree
that pericytes in the adult retina do not replicate, so there is only a finite number of pericytes in
the eyes of each person (Romeo et al., 2002). Interestingly, oxidative stress in the retina does not
have the same effect on vascular endothelial cells as it does pericytes. Although the pericytes
surrounding and supporting them are subject to apoptosis, the number of endothelial cells
remains constant. As an estimate, the ratio of pericytes to endothelial cells in the adult retina is
1:1 (Kowluru & Chan, 2007). In the diabetic retina, on the other hand, this ratio is reduced to 1:4
indicating a severe loss of pericytes with no significant change in the number of endothelial cells.
However, without the support of pericytes, the microvasculature of the retina is subject to
various kinds of damage.
Downstream Effects of Pericyte Apoptosis
Pericyte apoptosis leaves gaps in the support of blood vessels. In the sensitive
microenvironment of the retina, these small gaps of support put stress on the endothelial cells
and normal blood pressure can cause outpouching of the vessels (Wang & Lo, 2018).
Outpouching of the blood vessels commonly leads to blood vessel rupture and consequent retinal
bleeding and lipid deposits. Furthermore, in addition to activating Bax, NF-κB causes the release
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of TNF-α from pericytes (Romeo et al., 2002). As a cytokine, TNF-α can change endothelial cell
phenotype so they exhibit pro-inflammatory and pro-coagulant properties. These properties may
lead to capillary occlusions and further rupturing of the blood vessels. Excessive bleeding in the
retina causes neuronal cell death by glutamate excitotoxicity (Li & Puro, 2002). Typically, the
microenvironment of the retina has a relatively low concentration of glutamate because of the
action of Müller cells as described above. Blood, on the other hand, has a high concentration of
glutamate. When capillary occlusion or outpouching of the vessels leads to retinal bleeding, the
influx of blood greatly increases the retinal concentration of glutamate which kills the neuronal
cells of the retina by overexcitation.
Retinal blood vessel rupture causes damage to the eyes in other ways, too. For example,
one common symptom of diabetic retinopathy is diabetic macular edema (Wang & Lo, 2018).
Diabetic macular edema arises from breakdown of the blood retinal barrier and is the most
common cause of vision loss in patients with diabetic retinopathy (Duh et al., 2017). Typically,
loss of vision due to diabetic macular edema is the first noticeable symptom in patients with
diabetic retinopathy. The macula is the central portion of the retina and is responsible for
receiving light for perception of entities in sharp focus. When blood vessel permeability is
increased or blood vessels rupture, it can cause a fluid accumulation underneath the macula
disrupting vision by multiple mechanisms. First, fluid accumulation causes swelling of the
macula which disrupts the normal path of light from the surface of the retina to the
photoreceptors underneath (Daruich et al., 2018). Furthermore, the introduction of fluid to the
macula changes the refractive index of retinal layers. In short, light travels at different speeds
though different mediums. Fluid in the macula changes the speed by which light travels and
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therefore alters its path to the photoreceptors. For these reasons, patients with diabetic macular
edema often report experiencing metamorphopsia (Musat et al., 2015). This type of visual
impairment manifests itself by distorting images so straight lines seem curved.
Beyond diabetic macular edema, damage to blood vessels yields a decreased
transportation of nutrients such as oxygen. Less oxygen yields a further increase of ROS because
there is no recipient for the high-energy electrons from the electron transport chain. Yet, the
retina is affected by decreased oxygen transportation in more significant ways. At this stage in
the disease, the hallmark of proliferative diabetic retinopathy becomes evident, which is
angiogenesis (Al-Kharashi, 2018). In response to hypoxia and damage to the microvasculature,
endothelial cells release vascular endothelial growth factor (VEGF) which signals for an increase
in vascular permeability as well as endothelial cell proliferation. VEGF causes endothelial cells
to first secrete matrix metalloproteases (MMPs) which degrade the surrounding basement
membrane. New endothelial cells are then allowed to migrate away from their parent cells into
the gaps where the basement membrane has been degraded. Using adhesive molecules such as
integrins, these new endothelial cells begin proliferation in the extracellular matrix. It is this
proliferation that results in the formation of a network of new blood vessels.
Although angiogenesis is beneficial in some cases, such as the development of the retina,
angiogenesis in the adult diabetic is one of the main components of proliferative diabetic
retinopathy. First, the new blood vessels do not fix the problem for which they were developed.
New blood vessels are formed without a sense of direction. Therefore, most of them do not reach
the malnourished areas of the retina that signaled for angiogenesis in the first place (Fadini et al.,
2019). Moreover, the newly formed vessels are weaker than the parent vessels and more likely to
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rupture causing further damage to the retina via glutamate excitotoxicity. Rupturing of these new
vessels could potentially cause vision-decreasing hemorrhages in the vitreous humor of the eye
as well. Excessive glutamate excitotoxicity and prolonged hypoxia can culminate in death of
neuronal cells significant enough to cause blindness.
Furthermore, the new blood vessels occasionally invade the vitreous humor and cause
tractional retinal detachments (Fadini et al., 2019). When the vitreous is disrupted by the growth
of new blood vessels, it moves and pulls part of the retina with it causing severe damage to the
retina and potentially blindness. Finally, in some cases, the new vasculature grows into the angle
of the anterior chamber of the eye and obstructs the outflow of vitreous fluid. This causes an
accumulation of fluid inside the eye leading to increased intraocular pressure. This pressure
damages the optic nerve and progressively kills nerve cells from the outer portion of the retina
inwardly. This specific type of damage to the optic nerve is called neovascular glaucoma and can
also lead to blindness. Loss of retinal pericytes disrupts retinal homeostasis in a variety of ways.
Outlook for Diabetic Retinopathy
Diabetic retinopathy is a serious concern for an increasingly large population of
Americans. For this reason, it is important to understand the best treatment options as well as the
potential for better means of treatment in the future.
Current Treatment of Diabetic Retinopathy
When treating diabetic retinopathy, the first step is to target the source of the problem:
hyperglycemia. Traditionally, blood glucose levels are lowered by drugs such as metformin,
which acts as an insulin sensitizer, or by exogenous insulin administration, which is typically
done later in the progression of diabetes. For patients ranging anywhere from pre-diabetic to
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having elevated blood sugar for a decade or more, metformin is among the most commons drugs
prescribed (Viollet et al., 2012). Metformin is valuable because of its ability to lower blood
glucose levels without causing hypoglycemia. One of the main roles of metformin in the
reduction of blood glucose levels is to act as an insulin sensitizer. By upregulating expression of
the insulin receptor in the body’s tissues, metformin causes increased insulin sensitivity and
glucose uptake. Consequently, blood glucose concentrations are better regulated.
Further downstream in the progression of diabetes, exogenous insulin administration may
be utilized to lower glucose concentrations in the blood; however, doctors typically do not start
this type of treatment until ten to fifteen years after diagnosis with diabetes (Swinnen et al.,
2009). The reason physicians and patients are wary to start exogenous insulin therapy is because
it can cause hypoglycemia and weight gain. Furthermore, the administration involves painful
injections that must be done on a regular basis. Although there are clear drawbacks to exogenous
insulin therapy, studies have demonstrated great benefits from using insulin early in the
treatment of diabetes. Early insulin therapy has beneficial effects on the β-cells of the pancreas
(Weng et al., 2008). Studies suggest that early insulin administration improves β-cell function
and has positive implications on patient remissions. Moreover, early insulin therapy benefits the
retina. Usage of insulin within the first month of diagnosis with diabetes results in fewer
apoptotic cells in the retina (Barber et al., 1998). Metformin and insulin are both beneficial
therapies for treating the root of diabetic retinopathy, but other treatment options are used to
directly ameliorate damage to the retina.
In treatment of diabetic retinopathy, by far the most widely used therapy is anti-VEGF
therapy. The goal of anti-VEGF therapy is to stop angiogenesis and thus prevent further damage
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to the retina through hemorrhages, retinal detachments, and neovascular glaucoma. Two of the
most common anti-VEGF agents are ranibizumab and bevacizumab; both work in similar ways.
Ranibizumab is a recombinant, humanized, monoclonal antibody fragment with a high affinity to
VEGF (Gaudreault et al., 2005). Likewise, bevacizumab is a humanized immunoglobulin G
antibody with a high affinity to VEGF (Krämer & Lipp, 2007). Both antibodies bind to VEGF in
the circulation of retinal microvasculature so it cannot bind to its receptor to promote
angiogenesis. The downside of using these anti-VEGF agents is that ranibizumab and
bevacizumab have half-lives of approximately 3 days and 20 days, respectively (Gaudreault et
al., 2005; Krämer & Lipp, 2007). Thus, the agents, which are administered by intravitreal
injections, must be given weekly, biweekly, or triweekly.
The next most common treatment for the diabetic retina is laser photocoagulation.
Photocoagulation techniques were one of the first treatments of diabetic retinopathy, and
although this treatment option is used less frequently since the advent of anti-VEGF therapy, it is
still used somewhat commonly as a viable means to treat the diabetic retina. Laser
photocoagulation works by applying focused, high-energy light to specific regions of the retina
to cauterize broken blood vessels or kill small regions of retinal cells (Everett & Paulas, 2021).
Cauterizing broken blood vessels stops retinal bleeding. Killing retinal cells in areas of poor
perfusion decreases the demand for oxygen and other nutrients in that portion of the retina
thereby reducing oxidative stress and VEGF secretion. In many cases, the brain is able to ignore
the gaps in photoreceptive information and still produce a reliable image. However, in some
cases, laser photocoagulation has caused permanent damage to the retina resulting in mild central
vision loss and reduced night vision (Wang & Lo, 2018). Treatments for diabetic retinopathy are
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beneficial in many ways, but further research is needed to discover treatment options without
serious drawbacks.
Potential Treatment Options for Diabetic Retinopathy
Because diabetic retinopathy is such a prevalent and prominent complication of diabetes,
researchers are constantly searching for new treatment options. Among the most recent research,
some of the promising potential treatments for diabetic retinopathy include inhibiting fatty acid
synthase (FASN) to prevent angiogenesis and treatment with adipose-derived stromal cells
(ASC) as a means of repairing the retinal microenvironment.
Research done by Bruning et al. (2018) sought to determine the effects of FASN
inhibition on angiogenesis. An analysis of endothelial cells with a FASN knockout as well as
after treatment with the FASN inhibitor orlistat demonstrated that decreased FASN activity
affected endothelial cell proliferation and migration. This was done by the use of a scratch
wound migration assay and a spheroid capillary sprouting assay. In the former, the research team
reported minimal changes in migration due to FASN knockout or inhibition. In the latter,
however, there was a significant decrease in the endothelial cell proliferation in response to
FASN knockout and inhibition. From this data, the researchers concluded that FASN inhibition
causes a decrease in angiogenesis by impairing endothelial cell proliferation. This research
informs the scientific community of a potential use of FASN inhibition in the treatment of
diabetic retinopathy.
Other researchers have explored the potential of using ASC as a means to cure the
diabetic retina. Kremer et al. (2020) conducted research to compare ASC to retinal pericytes.
Before this research was done, other studies in diabetic retinopathy models had demonstrated
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that ASC therapy could potentially provide a cytoprotective and reparative environment for
damaged endothelial cells and pericytes. ASC have anti-inflammatory and anti-apoptotic
properties to help slow progression of diabetic retinopathy. In addition, ASC integrate
themselves into the retina to replace detached pericytes and provide support for the
microvasculature. Despite all these benefits, clinical trials have not been completely successful,
so Kremer and his colleagues conducted research to further the scientific community’s
understanding of ASC.
To explore the potential for ASC therapy in diabetic retinopathy, the research team first
analyzed the adhesion of both pericytes and ASC to endothelial cells in high-glucose conditions
(Kremer et al., 2020). The result was that high-glucose impaired pericyte adhesion but had no
effect on ASC adhesion. In addition, Kremer and his team set up an angiogenesis assay to
compare angiogenic properties of ASC to pericytes. In contrast to pericytes which had
angiostatic properties, ASC caused angiogenesis in endothelial cells similarly to the positive
control, VEGF. Finally, Kremer and colleagues tested the effects of VEGF receptor 2 (VEGFR2) inhibitor ZM 3238811. In the presence of ZM 3238811, ASC angiogenic activity was
decreased indicating that the pro-angiogenic activity of ASC is mostly due to VEGF signaling.
The results of this research suggest that clinical trials may not have been successful due to the
angiogenic activity of ASC. Moreover, this study provides reason to pursue ASC therapy in
combination with anti-VEGF therapy as means to treat diabetic retinopathy.
Conclusion
As diabetes is continuing to affect more people every year, the number of people who
develop diabetic retinopathy will only increase in the foreseeable future. For this reason, the
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importance of understanding this disease’s pathogenesis as well as the potential for therapy
cannot be stressed enough. Although diabetic retinopathy has serious implications for the eyes,
researchers have found viable treatment options to ameliorate symptoms. Furthermore, current
research seems to hold great potential for even better treatment options in the not-too-distant
future. The pathogenesis of diabetic retinopathy progressing from the disruption and apoptosis of
α-cells and β-cells in the pancreas leading to dysfunction and apoptosis of Müller cells and
pericytes in the retina truly is an intricate and intriguing process.
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